AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: AZD1236Drug: Placebo
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00767052
- Locations
- 🇯🇵
Research Site, Osaka-city, Osaka, Japan
14729-D9831C00002- 1 Month Biopsy Study
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: AZD1981Drug: Placebo
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT00766415
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2009-08-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 132
- Registration Number
- NCT00766012
- Locations
- 🇯🇵
Research SIte, Fukuoka, Japan
AZD8529 Multiple Ascending Dose Study in Healthy Subjects
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2009-06-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT00765492
Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2009-03-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00766025
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 261
- Registration Number
- NCT00765817
- Locations
- 🇺🇸
Research SIte, New York, New York, United States
🇬🇧Research Site, Torquay, United Kingdom
Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS
Terminated
- Conditions
- Endometriosis
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2009-09-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT00761683
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT00761501
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
Phase 2
Completed
- Conditions
- Anxious Major Depressive Disorder
- Interventions
- Drug: PlaceboDrug: AZD2327
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2012-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT00759395
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: AZD1236Drug: Placebo
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2011-08-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 74
- Registration Number
- NCT00758459
- Locations
- 🇸🇰
Research Site, Zilina, Slovakia
© Copyright 2025. All Rights Reserved by MedPath